High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer

Qiu, Siqi; Rooijen, Johan van; Nienhuis, Hilde H.; Vegt, Bert van der; Timmer‐Bosscha, Hetty; Leeuwen-Stok, Elise van; Walenkamp, Annemiek; Deurzen, Carolien H.M. van; Bock, Geertruida H. de; Vries, Elisabeth G.E. de; Schröder, Carolien P.

doi:10.1186/s13058-020-01266-x

Cited by 8 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study of 720 MBCs studying hepatocyte growth factor (HGF) and CXCL12 expression in tumour tissue by Qiu et al observed that high HGF expression in tumour cells was an independent predictor for better OS in nonmetastatic setting (13.0 years compared to 7.5 years in HGF low expressing tumours). High expression of CXCL12 in cytoplasm of tumour cells was also associated with better OS [25].…”

Section: Prognosismentioning

confidence: 88%

See 1 more Smart Citation

Male Breast Cancer: An Updated Review of Patient Characteristics, Genetics, and Outcome

Khare,

Huda,

Misra

et al. 2024

International Journal of Breast Cancer

View full text Add to dashboard Cite

Male breast cancer (MBC) is a rare entity, underrepresented in population studies and clinical trials, resulting in management of MBC to be informed by current research on female breast cancer (FBC). A literature review was conducted by accessing relevant articles on 2 databases, by searching keywords “male breast cancer”. A total of 29 articles from year 2011 to 2022 were selected for this review. The authors found that male breast cancer generally occurs later in life with higher stage, higher grade, and more estrogen receptor (ER) positive tumours. Most of the studies noted the mean age for MBCs at the time of presentation as >60 years. Risk factors for male breast cancer include family history, obesity, lower physical activity, and syndromes like the Klinefelter syndrome. Positive family history is much higher in MBC compared to FBC (30.9 vs. 18.4%). BRCA 2 cancers constitute a higher proportion compared to FBCs. A lot of genetic mutations have been observed. Some show promise to assess disease-specific survival and proliferative rate like TWIST1 and RUNX3, among others. MBCs usually present with a palpable lump in central region, with a bigger size and chance of nodal involvement and metastasis compared to FBCs. They are mostly infiltrating ductal type and hormone receptor positive, with worse histological grade. Treatment usually follows the same principles as FBCs (systemic therapy, surgical excision, and radiotherapy), with poorer prognosis to same treatment approach, possibly owing to its advanced stage at presentation. This is a rare entity which requires further research to ascertain need for different management approach than FBCs.

show abstract

Section: Prognosismentioning

confidence: 88%

“…The median H-score (<20% difference in percentage) for CXCL12 expression was 100 both in cytoplasm and in nucleus. The median H-score for HGF expression was 106 [25].…”

mentioning

confidence: 99%

Male Breast Cancer: An Updated Review of Patient Characteristics, Genetics, and Outcome

Khare,

Huda,

Misra

et al. 2024

International Journal of Breast Cancer

View full text Add to dashboard Cite

show abstract

“…Also two separate meta-analyses examining the prognostic value of c-MET overexpression by a variety of RNA and protein-based detection methods concluded that c-MET overexpression is associated with both breast cancer recurrence and overall survival [32,33]. In contrast, a large Dutch male breast cancer cohort (n = 841) found that HGF protein expression (as measured by immunohistochemistry) was protective against overall survival [34]; however, this population is quite distinct and male breast cancer is predominantly of luminal subtype, which we found to have lower prevalence of HGF expression [34,35]. Our results add important new data based on a large, diverse study population.…”

Section: Discussionmentioning

confidence: 99%

Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression

Jones

Hoadley

Benefield

et al. 2022

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Black women have a 40% increased risk of breast cancer-related mortality. These outcome disparities may reflect differences in tumor pathways and a lack of targetable therapies for specific subtypes that are more common in Black women. Hepatocyte growth factor (HGF) is a targetable pathway that promotes breast cancer tumorigenesis, is associated with basallike breast cancer, and is differentially expressed by race. This study assessed whether a 38-gene HGF expression signature is associated with recurrence and survival in Black and non-Black women. Methods Study participants included 1957 invasive breast cancer cases from the Carolina Breast Cancer Study. The HGF signature was evaluated in association with recurrence (n = 1251, 171 recurrences), overall, and breast cancer-specific mortality (n = 706, 190/328 breast cancer/overall deaths) using Cox proportional hazard models. Results Women with HGF-positive tumors had higher recurrence rates [HR 1.88, 95% CI (1.19, 2.98)], breast cancer-specific mortality [HR 1.90, 95% CI (1.26, 2.85)], and overall mortality [HR 1.69; 95% CI (1.17, 2.43)]. Among Black women, HGF positivity was significantly associated with higher 5-year rate of recurrence [HR 1.73; 95% CI (1.01, 2.99)], but this association was not significant in non-Black women [HR 1.68; 95% CI (0.72, 3.90)]. Among Black women, HGF-positive tumors had elevated breast cancer-specific mortality [HR 1.80, 95% CI (1.05, 3.09)], which was not significant in non-Black women [HR 1.52; 95% CI (0.78, 2.99)]. Conclusion This multi-gene HGF signature is a poor-prognosis feature for breast cancer and may identify patients who could benefit from HGF-targeted treatments, an unmet need for Black and triple-negative patients.

show abstract

“…Statistical analysis was performed using SPSS version 19 software (IBM Corp.) and data are presented as the mean ± SEM. Survival rate analysis was analyzed using the Kaplan-Meier method, with a log-rank test used for comparison ( 20 ). Statistical differences between groups were determined using a one-way ANOVA, followed by a Student-Newman-Keuls test for multiple comparisons.…”

Section: Methodsmentioning

confidence: 99%

Ulinastatin attenuates lipopolysaccharide‑induced cardiac dysfunction by inhibiting inflammation and regulating autophagy

et al. 2020

View full text Add to dashboard Cite

Ulinastatin exerts protective effects against lipopolysaccharide (LPS)-induced cardiac dysfunction. Autophagy has been demonstrated to serve an important role in sepsis-induced cardiomyopathy; however, whether ulinastatin has an anti-autophagic effect in sepsis requires further investigation. The present study aimed to determine the protective effects of ulinastatin on cardiac dysfunction and its role in autophagy during sepsis. C57BL/6J mice were randomly divided into a control, LPS and LPS + ulinastatin group, the survival status of the mice was observed every 6 h and the survival rate at each time point was calculated for 7 days. Furthermore, JC-1 dye and ELISAs were used to analyze the mitochondrial membrane potential (MMP) and serum cardiac troponin I (cTnI) levels, respectively. Western blotting and ELISAs were used to measure the levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6. In addition, the cardiac ultrastructure and the number of autophagosomes formed were visualized using transmission electron microscopy, and the pathological changes in the myocardial tissues were analyzed using hematoxylin & eosin staining. Finally, the expression levels of autophagy-related proteins were analyzed using western blotting and immunofluorescence staining. The current study indicated that ulinastatin significantly improved the survival rate of septic mice. It was suggested that ulinastatin may protect against LPS-induced myocardium injury through its anti-inflammatory activity, as decreased cTnI levels, increased MMP and decreased expression levels of TNF-α and IL-6 were all observed following ulinastatin treatment. Furthermore, the number of autophagosomes formed, and the expression levels of microtubule-associated protein light chain 3 and Beclin 1 were significantly decreased following ulinastatin treatment. It was further observed that ulinastatin suppressed LPS-induced autophagosome formation, as indicated by the accumulation of sequestosome 1/p62, and the elimination of lysosome-associated membrane glycoprotein 1. In conclusion, the results of the present study suggested that ulinastatin treatment may improve survival and exert a protective effect over LPS-induced cardiac dysfunction. Furthermore, this protective effect may be associated with its anti-inflammatory and anti-autophagic activity.

show abstract

High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer

Cited by 8 publications

References 36 publications

Male Breast Cancer: An Updated Review of Patient Characteristics, Genetics, and Outcome

Male Breast Cancer: An Updated Review of Patient Characteristics, Genetics, and Outcome

Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression

Ulinastatin attenuates lipopolysaccharide‑induced cardiac dysfunction by inhibiting inflammation and regulating autophagy

Contact Info

Product

Resources

About